SIGN UP
LOG IN
E
EVOK
Evoke Pharma Inc
2.58
-0.01-0.39%Closed16:00 04/25 EDT
OPEN/PREV CLOSE2.600/2.590
TODAY RANGE2.362-2.620
VOL13.90K
MARKET CAP3.85M
52 WEEK RANGE1.940-12.32
AVG VOL (3M)17.83K
% TURNOVER0.93%
TURNOVER--
P/E (TTM)-0.9183
% RANGE9.79%
EPS(TTM)-2.8094
P/E(FORWARD)-3.1852
P/B0.5447
BVPS4.736
DIVIDEND--
P/S0.3741
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP3.64M
SHARES OUTSTANDING1.49M
NEXT EARNINGS05/12-05/16
FREE FLOAT1.41M
LOT SIZE1
EX-DIV DATE08/01/2024
News
Press Releases
Financial Reports
Profile
Press release·04/07 09:26
EVOKE PHARMA, INC. FORM 10-K — ANNUAL REPORT For the Fiscal Year Ended December 31, 2024
Benzinga·03/31 21:05
12 Health Care Stocks Moving In Monday's After-Market Session
Press release·03/13 21:00
EVOKE PHARMA, INC. FORM 10-K — ANNUAL REPORT For the Fiscal Year Ended December 31, 2024
Benzinga·03/13 20:14
Evoke Pharma Q4 Sales $3.31M Beat $3.08M Estimate
Seeking Alpha·03/13 20:13
Evoke Pharma GAAP EPS of -$0.49 beats by $0.14, revenue of $3.3M beats by $0.22M
Dow Jones·03/13 20:05
*Evoke Pharma 4Q Rev $3.3M >EVOK
Dow Jones·03/13 20:04
*Evoke Pharma Sees 2025 Rev $16M >EVOK
Reuters·03/13 20:02
EVOKE PHARMA INC: PROJECTS NET REVENUE IN 2025 OF APPROXIMATELY $16 MLN
Dow Jones·03/13 20:02
Press Release: Evoke Pharma, Inc. Reports Fourth -2-
Benzinga·03/13 08:32
Earnings Scheduled For March 13, 2025
Same Industry
Name/Symbol
Change%
Price
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.